FPA-157

N/A

Report date: 2025/01/03 14:50:06

Base Information

Drug NameFPA-157
Drug Alias NameFPA-157
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes inhibitorsC-C chemokine receptor type 8 inhibitors
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFive Prime Therapeutics IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesFive Prime Therapeutics Inc
Inactive CompaniesEeig Bristol-Myers Squibb Manufacturing Company Bristol-Myers Squibb Srl
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A